Skip To Main Content
Deze website is alleen bedoeld voor zorgverleners van België en Luxemburg.
Campus
  • Wetenschap
  • Artikelen
  • Opleiding
  • Andere onderwerpen
Campus
  • Wetenschap
  • Artikelen
  • Opleiding
  • Andere onderwerpen

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden
Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Leer meer
Cardiovascular diseases (CVDs) are the leading cause of death globally<sup>1</sup>

Cardiovascular diseases (CVDs) are the leading cause of death globally

Leer meer
Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Leer meer
How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Leer meer
Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Leer meer
When to suspect TTP?

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Leer meer
What is TTP? A rare, life-threatening medical emergency

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Leer meer
Signs and symptoms of aTTP

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Leer meer
The Complex Burden of Autoimmune Type 1 Diabetes

The Complex Burden of Autoimmune Type 1 Diabetes

Leer meer
Why choose PRALUENT<sup>®</sup>?

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2

Leer meer
Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP

Navigating the Complexities of Smell Loss in Patients with CRSwNP.

Leer meer
What is PRALUENT<sup>®</sup>?

What is PRALUENT®?

PRALUENT®: a powerful PCSK9i that ticks all the boxes1–4

 

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.2 It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.2 Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.1

Leer meer